ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Aberrant C-terminal domain of polymerase η targets the functional enzyme to the proteosomal degradation pathway

Ahmed Seghir S; Pouvelle C; Despras E; Cordonnier A; Sarasin A; Kannouche P L
DNA Repair2015DOI: 10.1016/j.dnarep.2015.02.017
5被引9阅读
引用收藏
分享

摘要

Xeroderma pigmentosum variant (XP-V) is a rare genetic disease, characterized by sunlight sensitivity and predisposition to cutaneous malignancies. XP-V is caused by a deficiency in DNA polymerase eta (Polη) that plays a pivotal role in translesion synthesis by bypassing UV-induced pyrimidine dimers. Previously we identified a new Polη variant containing two missense mutations, one mutation within the bipartite NLS (T692A) and a second mutation on the stop codon (X714W) leading to a longer protein with an extra 8 amino acids (721 instead of 713 AA). First biochemical analysis revealed that this Polη missense variant was barely detectable by western blot. As this mutant is extremely unstable and is nearly undetectable, a definitive measure of its functional deficit in cells has not been explored. Here we report the molecular and cellular characterization of this missense variant. In cell free extracts, the extra 8 amino acids in the C-terminal of Polη721 only slightly reduce the bypass efficiency through CPD lesions. In vivo, Polη721 accumulates in replication factories and interacts with mUb-PCNA albeit at lower level than Polηwt. XP-V cells overexpressing Polη721 were only slightly UV-sensitive. Altogether, our data strongly suggest that Polη721 is functional and that the patient displays a XP-V phenotype because the mutant protein is excessively unstable. We then investigated the molecular mechanisms involved in this excessive proteolysis. We showed that Polη721 is degraded by the proteasome in an ubiquitin-dependent manner and that this proteolysis is independent of the E3 ligases, CRL4cdt2 and Pirh2, reported to promote Polη degradation. We then demonstrated that the extra 8 amino acids of Polη721 do not act as a degron but rather induce a conformational change of the Polη C-terminus exposing its bipartite NLS as well as a sequence close to its UBZ to the ubiquitin/proteasome system. Interestingly we showed that the clinically approved proteasome inhibitor, Bortezomib restores the levels of Polη721 suggesting that this might be a therapeutic approach to preventing tumor development in certain XP-V patients harboring missense mutations.

学科与关键词

关键词
BortezomibMG132Translesion synthesisUbiquitin/proteasome systemUltravioletXeroderma pigmentosum variantXP-V
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
DNA Repair
发表日期
2015
卷期
第 29 卷
页码
154-165
DOI
10.1016/j.dnarep.2015.02.017
语言
ENGLISH
期刊收录
SCIE
期刊等级
Q2
成果收录
SCOPUS

作者

  • A

    Ahmed Seghir S (第一作者)

  • P

    Pouvelle C

查看全部 6 位作者收起作者
  • D

    Despras E

  • C

    Cordonnier A

  • S

    Sarasin A

  • K

    Kannouche P L

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417